© 2021 MJH Life Sciences and Cancer Network. All rights reserved.
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
May 19, 2010
The AACR and ACCC elect new leaders. Read more about the latest accolades and appointments in the cancer care community.
May 17, 2010
In today’s contentious debate over how to best deliver cost-effective, value-added healthcare, insurers have become the villain du jour, taking a backseat only to Wall Street fat cats.
There’s no shortage of controversy when it comes to mammography-based breast cancer screening.
Trelstar (22.5 mg triptorelin pamoate) has received FDA marketing approval as a twice-yearly intramuscular gonadotropin-releasing hormone (GnRH) agonist.
Whole-body MRI should be the go-to imaging modality for detecting bone metastases in asymptomatic patients.
Typically glioblastoma patients are dead within 15 months of diagnosis, no matter how complete and well-planned their therapy.
Eli Lilly has joined SNM’s Clinical Trials Network, a collaborative effort designed to address the need for validated imaging biomarkers for streamlining the development and registration of investigational therapeutics.
Patients who receive chemotherapy after surgery for gastric cancer have a higher rate of survival compared to those patients who have surgery alone.
Opening of the Maggie Daley Center for Women’s Cancer Care at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
A multi-institutional group of researchers have zeroed in on a more accurate way to decipher treatment outcomes in young leukemia patients using information from a simple complete blood count test.
Cabazitaxel, an investigational taxane, significantly extended survival among prostate cancer patients whose disease had progressed despite hormone therapy.
Adding gemcitabine (Gemzar) to concurrent radiotherapy and cisplatinum in invasive bladder cancer could preserve the organ even when the tumor has invaded the muscle.
The p90 ribosomal S6 kinase protein contributes to tumor cell proliferation and survival, the genetic disease Carney complex, and cardiac hypertrophy.
Coverage in most countries is universal, but limited resources can sometimes hinder how much coverage a person can expect.
Tests carry a significant price tag, but reduction in chemotherapy use is potentially cost-saving.
The technique provides a new and continuously evolving tool in oncologic imaging for lesion detection, characterization, and therapy assessment.
Parents and their children need to understand that advancing science does not always go hand-in-hand with a direct benefit to the patients.
May 13, 2010
An NCI report concluded that our clinical trial system is nearing a “state of crisis.” This seems like a case of new report, same conclusion.
A medical oncologist, a radiation oncologist, and a surgeon share pearls and pitfalls in their specialized approaches to managing recurrent disease.
Survey results indicate patient access schemes in the UK and the U.S. need refinement.
The I-SPY 2 breast cancer trial features a novel design of uninterrupted enrollment and patient stratification using biomarkers in order to target therapy.
PET paired with a variety of radiotracers offers insights into the metabolic, DNA, and protein pathways.
Rules balance access to promising new therapies against the need to protect patient safety.